EBITDA

Family safety app Life360 acquires ad-tech firm Nativo, using its vast location data to build an ad empire. Can it balance profit with user privacy?

KIOXIA's new BG7 SSDs use breakthrough BiCS FLASH Gen 8 and CBA tech to deliver major speed and power efficiency gains for the next generation of PCs.

A new health initiative aims to fight chronic disease with personalized nutrition. But can data from your body truly fix a broken food system?

At CES 2026, Ubicept's new toolkit promises to let AI see clearly in the dark and at high speed, ushering in a new era for robotics and autonomous cars.

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

Fintech firm Movemint's rebrand signals a major shift for banks, focusing on embedded finance and personalized experiences to drive measurable growth.

Founder Chuck Cohn pours millions more into his ed-tech firm, a bold move that signals deep confidence despite a slumping stock and cautious analysts.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

QuinStreet's major acquisition of HomeBuddy aims to reshape the digital home services market by combining scale with exclusive, high-intent contractor leads.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

Off The Hook's new luxury division leverages AI and an integrated model to secure ~$100M in listings and close 22 deals in its explosive first quarter.

A new integration brings Ceres AI's insights directly into the John Deere Operations Center, tackling data fragmentation for growers and insurers alike.

Amid a capacity crisis, a new model blending AI with human oversight gains traction, promising efficiency without sacrificing the crucial element of patient care.

With record Q3 earnings and strong analyst ratings, Red Violet is set to present its identity intelligence growth strategy at the prestigious Needham conference.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

A premium meal service enters the D.C. market not with ads, but with community aid and a rare, profitable business model that defies industry trends.